| abstract |
Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heterocyclyl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 1 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 represents hydrogen or C1-6alkyl; and salts and solvates thereof are CCR-3 antagonists and are thus indicated to be useful in therapy. |